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acute care utilization in MF TD patients. Potential short term and long term benefits 
of ICT in MF need to be validated in prospective clinical trials.
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Objectives: Gaucher disease (GD) is a rare genetic disorder characterized by the 
accumulation of lipid glucosylceramide in organs such as the spleen, liver and bone 
marrow. Based operationally on the presence and severity of central nervous system 
manifestations, GD is classified into three types (GD1, GD2, and GD3), although GD1 
is the predominant type diagnosed in most regions. However, the epidemiology of 
GD is not well established. MethOds: A comprehensive review of English language 
literature primarily focusing on the incidence and prevalence of GD was performed. 
Literature indexed in MEDLINE, EMBASE, and CENTRAL and published between 
January 1990 and February 2013 was searched. “Grey literature” sources from key 
congresses were also searched. Results: 22 studies of the epidemiology of GD 
from North America, Europe, Israel, Australia, and Japan were identified. Nine stud-
ies estimated prevalence of GD in the general population at 0.33–1.75 per 100,000. 
The prevalence was higher in populations of Ashkenazi Jewish descent, ranging 
from 82.8–222.2 per 100,000. Seven studies reported GD incidence using a general 
population, while one study screened Ashkenazi Jews to identify carrier couples 
of GD mutations in Israel. The incidence of GD varied among studies performed in 
the general population from 0.30–5.80 per 100,000. The highest incidence rate was 
reported in Austria, where newborns were prospectively screened for mutations in 
the cognate GBA1 gene, thus likely increasing the cases diagnosed in this popula-
tion. The estimated carrier frequency of four GBA mutations among individuals of 
Ashkenazi Jewish descent was 5.7%, and the frequency of affected fetuses in carrier 
couples who underwent prenatal diagnosis was 23.5%. cOnclusiOns: GD is a rare 
disorder that disproportionately affects individuals of Ashkenazi Jewish descent. 
The observed variability of GD incidence and prevalence may be explained by dif-
ferences in the studied population, region, study design, and diagnostic criteria.
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Objectives: To estimate the safety and tolerability of azacitidine in those suffer-
ing from intermediate-2 and high risk Myelodysplastic Syndromes (MDS), in a real 
world setting in Greece. MethOds: A nationwide, retrospective chart review study 
was conducted, based on 17 Hematology departments of Hospitals throughout the 
country. Eligible patients were analyzed concerning the frequency of Serious and 
Non-Serious-Adverse Drug Reactions (SADRs/NSADRs). By definition, a SADR could 
result death, life-threatening condition, significant disability, requires hospitaliza-
tion or might be considered medically important. Any reaction which does not 
fulfill the above description is a NSADR. Patients were recruited if were > 18 years 
and were alive at the time of their data collection, they have completed at least one 
evaluation after azacitidine treatment initiation and at least one cycle of azacitidine 
treatment regardless of the outcome. The study was conducted in accordance with 
the declaration of Helsinki. Results: The incidence of NSADRs and SADR during 
treatment was 50% and 42%, respectively. The most commonly reported NSADRs 
were neutropenia (11.4%), thrombocytopenia (9.1%), pyrexia (8.0%) and constipation 
(8.0%). Regarding their intensity, 45.7% of NSADRs were grade I, 43.6% were grade 
II, and 10.6% were grade III. None of the NSADRs resulted in patient hospitaliza-
tion. The most commonly reported SADRs were thrombocytopenia (13.6%), pyrexia 
(10.2%), neutropenia (9.1%), febrile neutropenia (4.5%), anaemia and respiratory tract 
infection (both 4.5%). 48.6% of all SADRs were grade III,while 18% were grade IV. In 
20.8% of SARDs no action was taken, 1.4% resulted in permanent discontinuation, 
while temporary treatment interruption was required for 34.7% of patients. 30.7% of 
patients experienced any SADRs, required hospitalization. cOnclusiOns: In this 
study, the safety and tolerability of azacitidine for intermediate-2 and high risk MDS 
patients was descriptively analyzed based on Greek data. A broader, real life, analysis 
is needed to reach more decisive conclusions in the local setting.
SYSTemic diSorderS/condiTionS – cost Studies
PSY13
increaSing bariaTric Procedure volume in briTiSh columbia, 
canadaa budgeT imPacT analYSiS over 10 YearS
Goldstein LJ
Johnson & Johnson Medical Companies, Markham, ON, Canada
Objectives: British Columbia (BC) currently performs around 250 bariatric pro-
cedures annually. The number of individuals eligible for bariatric surgery in BC is 
approximately 87,000 and is increasing at about 1.04% annually. Obese individuals 
are high volume users of the health care system and bariatric surgery has proven to 
be an effective intervention for weight loss and for reducing the impact of obesity-
related disease. The objective of this study was to determine the budget impact of 
increasing the volume of bariatric procedures performed in BC to include 1% of all 
eligible patients each year. MethOds: A budget impact model accounting only 
for direct health care costs was created using data from Statistics Canada, peer-
reviewed literature, the Canadian Institute for Health Information and case-costing 
Objectives: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune 
condition characterized by increased platelet destruction and suboptimal platelet 
production, resulting in low platelet counts (thrombocytopenia). Romiplostim has 
shown efficacy in increasing platelet counts. The objective of this study was to 
conduct meta-analysis and present total evidence for Romiplostim for treatment 
of ITP. MethOds: For this meta-analysis we included randomized controlled tri-
als (RCTs) evaluating Romiplostim for the treatment of ITP. We included RCTs that 
compared romiplostim versus placebo for management of ITP, had a treatment 
duration of at least 24 weeks, were doubleblind (patients and investigators blinded) 
and reported data on platelet response. A systematic literature search for Etanercept 
trials was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar, 
and Cochrane. Data was collected for the study size, interventions, year, and the 
two outcomes overall and durable platelet response rate. For meta-analysis, random 
effects and fixed effects models were used to obtain cumulative statistics. Results: 
Two RCTs with a total of 125 patients were identified. The pooled response rates 
for Romiplostim for overall platelet response rate were 82% (95% CI 73%-90%); and 
for durable platelet response rate were 48% (95% CI 26%-71%). The pooled response 
rates for placebo for overall platelet response rate were 7% (95% CI 0%-15%), and for 
durable platelet response rate were 2% (95% CI 0%-4%). For overall platelet response 
rate the cumulative relative risk with placebo versus Romiplostim was 0.09 (95% CI 
4%-14%). For durable platelet response rate, the cumulative relative risk with placebo 
versus Romiplostim was 0.03 (95% CI 0%-6%). cOnclusiOns: Meta-analysis shows 
Romiplostim offers patients with Immune idiopathic thrombocytopenia an effective 
therapeutic option for increasing platelet counts.
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Objectives: Obinutuzumab (GA101) is a novel, glycoengineered, type II CD20 anti-
body. In the phase 3 CLL11 trial, chlorambucil (Clb) plus GA101 (G-Clb) significantly 
prolonged progression-free survival (PFS) compared with either Clb alone or rituxi-
mab plus Clb in previously untreated patients with chronic lymphocytic leukemia 
(CLL) and comorbidities. We present indirect treatment comparisons (ITCs) of G-Clb 
versus bendamustine (Benda), and ofatumumab plus Clb (Ofat-Clb). MethOds: We 
conducted a systematic review of non-randomized and randomized controlled trials 
(RCTs) to assess the clinical efficacy and safety of pharmacological interventions 
for previously untreated CLL; manuscripts (Jan 1992 to Mar 2013), abstracts (includ-
ing hand-searching; Jan 2010 to Mar 2013), and in-progress trials were screened for 
inclusion. Based on extracted data, a feasibility assessment of quantitative analysis 
was undertaken. ITCs of G-Clb versus Benda and G-Clb versus Ofat-Clb were derived. 
The WinBUGS code used to parameterize the fixed-effect network meta-analysis 
model used a natural logarithm of the hazard ratios (HR) for PFS as the (continuous) 
outcome variable. Results: Of the 4,819 publications identified, 262 manuscripts 
and 13 abstracts were selected for detailed evaluation. Following de-duplication of 
publications, the data set included 28 RCTs (157 publications) and nine non-RCTs 
(14 publications). ITCs were based on HR and 95% confidence intervals (CIs) reported 
for G-Clb in the CLL11 trial, for Benda in the Knauf et al. publications, and for Ofat-
Clb in the Complement 1 trial. The ITC for G-Clb versus Benda had a HR (95% CI) 
of 0.53 (0.35-0.77) and the ITC for G-Clb versus Ofat-Clb had a HR (95% CI) of 0.33 
(0.22-0.47). cOnclusiOns: Based on the ITCs of available evidence in this indica-
tion, G-Clb is expected to improve PFS rates compared with Benda or Ofat-Clb. How 
this benefit will translate into overall survival differences will be assessed when the 
available data are more mature.
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Objectives: To compare incidence of myelofibrosis (MF)-related complications and 
all-cause and MF-related resource utilization (RU) in blood transfusion-dependent 
(TD) MF patients treated with vs. without iron-chelating therapy (ICT+ vs. ICT-).  
MethOds: Two commercial health care claims databases, Truven MarketScan 
(2000-2012) and PharMetrics (2001-2012), were analyzed. Patients with ≥ 2 MF ICD-9 
diagnosis codes ≥ 30 days apart and ≥ 18 years at first MF diagnosis were included. 
First evidence of TD (index date) was defined as ≥ 3 transfusion events within any 
3-month period. Adjusted incidence rate ratios (aIRRs) of MF-related complications 
and all-cause and MF-related RU in TD ICT+ vs. ICT- patients were assessed using 
Poisson regressions, controlling for baseline comorbidities and MF-related com-
plications. Results: Of the 571 eligible TD MF patients, 103 (18%) were ICT+ and 
468 (82%) were ICT-. Mean age was similar between groups (ICT+: 67.2[SD: 10.4] 
vs. ICT-: 66.6[11.7]). Mean observation time was longer for ICT+ patients (months, 
22.2[13.9] vs. 12.6[11.6]). ICT- patients had higher mean Charlson Comorbidity Index 
(1.8[1.8] vs. 2.3[2.1]), suggesting a greater burden of comorbidities. Mean number 
of transfusion events/year was similar between groups (22.4[19.5] vs. 22.2[28.5]; 
p= 0.94). ICT+ patients had lower rates of thrombocytopenia (aIRR: 0.54; p< .001) and 
pancytopenia (0.53; p< .001). Rates of other MF-related complications were simi-
lar between groups. ICT+ patients had significantly lower rates of all-cause and 
MF-related ER visits (all-cause aIRR: 0.83 [95% CI: 0.72-0.95]) as well as inpatient stays 
(0.75 [0.64-0.87]) and days (0.52 [0.50-0.55]), but higher rates of outpatient visits (1.22 
[1.19-1.25]). cOnclusiOns: Despite similar complication profiles, ICT+ patients 
had significantly lower rates of acute care, but higher rates of outpatient care vs. 
ICT- patients, suggesting a possible link between closer monitoring and decreased 
